(19)
(11) EP 1 756 042 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.06.2014 Bulletin 2014/23

(45) Mention of the grant of the patent:
12.02.2014 Bulletin 2014/07

(21) Application number: 05733780.0

(22) Date of filing: 22.04.2005
(51) International Patent Classification (IPC): 
C07C 235/42(2006.01)
A61K 31/166(2006.01)
A61P 29/00(2006.01)
 C07D 213/89(2006.01)
A61K 31/4412(2006.01)
(86) International application number:
PCT/IB2005/001134
(87) International publication number:
WO 2005/105732 (10.11.2005 Gazette 2005/45)

(54)

SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS

SUBSTITUIERTE METHYLARYL- ODER HETEROARYLAMIDVERBINDUNGEN

COMPOSES METHYLARYL- OU HETEROARYLAMIDES SUBSTITUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

(30) Priority: 04.05.2004 US 568088 P

(43) Date of publication of application:
28.02.2007 Bulletin 2007/09

(73) Proprietor: RaQualia Pharma Inc
Chita-gun Aichi-ken 470 2341 (JP)

(72) Inventors:
  • KOIKE, Hiroshi., c/o SugiyamaDrugs Co.Ltd.,
    Aichi 464-8561 (JP)
  • MATSUMOTO, Yukari., c/o RaQualia Pharma Inc.,
    Chita-gun, Aichi 470-2341 (JP)
  • YAMAGISHI, Tatsuya., c/o RaQualia Pharma Inc.
    Chita-gun, Aichi 470-2341 (JP)
  • KON-I, Kana, c/o Pfizer Pharma Inc.,
    Chita-gun, Aichi 470-2393 (JP)
  • OKUMURA, Yoshiyuki., c/o AskAt Inc.,
    Chita-gun, Aichi 470-2341 (JP)
  • NAKAO, Kazunari.,
    Shizuoka 410-0011 (JP)

(74) Representative: HOFFMANN EITLE 
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München
81925 München (DE)


(56) References cited: : 
EP-A- 0 947 500
 WO-A-00/20371
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).